Wall Street equity research analysts tracking Evommune (NYSE: EVMN) maintain an optimistic consensus view, with the majority issuing Buy ratings and an average 12-month price target hovering significantly above its current trading level, driven by enthusiasm for its clinical-stage immunology pipeline.